The I-MOVE+ Consortium includes European Union (EU) Public Health Institutes, SME and Universities. It aims at measuring and comparing the effectiveness (VE) and impact (VI) of influenza and Pneumococcal vaccines and vaccination strategies a in the elderly population in Europe. The goal is to develop a sustainable platform of primary care practices, hospitals and laboratory networks that share validated methods to evaluate post marketing vaccine performances. The objectives are to identify, pilot test, and disseminate in EU the best study designs to measure, on a real time basis, VE (direct effect) and the VI of vaccination programmes (indirect and overall effect) against laboratory confirmed cases of influenza (types/subtypes) and pneumococcal disease (serotypes), and clinical outcomes. Cost effectiveness analysis will be conducted. Results will allow to understand factors affecting specific VE, the duration of protection of influenza and pneumococcal vaccines, the interaction between vaccines, the role of repeated vaccinations, the occurrence of serotype replacement (pneumococcus); identify vaccine types and brands with low VE; guide the decision of the WHO committees on vaccine strain selection (influenza); provide robust benefit indicators (VE and VI) and cost benefit and effectiveness results; guide vaccination strategies (schedules, doses, boosters). This EU member state collaboration will respond to questions that require studies based on large sample sizes and sharing of expertise that cannot be achieved by one country alone. It will allow the best methods to be used and results to benefit to all EU countries whatever their current public health achievements. Results will be shared with international partners.

The One Health concept recognizes that the human health is tightly connected to the health of animals and the environment, i.e. that animal feed, human food, animal and human health, and environmental contamination are closely linked. These are the main focus of our European joint programme (EJP). One reference laboratory from the public health / medicine domain and one reference laboratory from the food / veterinary domain are associated within a network of 41 European laboratories and research centers, distributed in 19 participating member states, with the aim to reach significant advances in the fields of foodborne zoonoses (FBZ), antimicrobial resistance (AMR) and emerging threats (ET) within a global One Health approach. Most of these laboratories have reference responsibilities, representing a sustainable framework for an integrated research community. Consistent with the “Prevent-Detect-Respond” concept, the One Health EJP aims at reinforcing collaboration between institutes by enhancing transdisciplinary cooperation and integration of activities by means of dedicated Joint Research Projects, Joint Integrative Project and through education and training in the fields of FBZ, AMR and ET. While alignment and harmonization with on-going EC-funded research project will also be considered, deliverables from the EJP activities should feed the approach of evidence based risk assessment and therefore the management of risks by the competent national authorities. Therefore, it is of utmost importance to efficiently and regularly updated the dissemination of knowledge between the research community and major International and European stakeholders, national authorities and further afield. The One Health EJP will also develop sustainable programs and projects beyond the lifetime of the EJP, through the production of a Strategic Research and Innovation Agenda (2021-2030) and a European P2P One Health Cooperative Joint Initiative.

EXEDRA, an EXpansion of the European Joint Programming Initiative on Drug Resistance to Antimicrobials, will build on, and further support the structure and activities of JPIAMR to address the two major objectives of HCO-04-2016 topic: extending JPIAMR globally and creating a long-term sustainable structure for future expansion and governance which will coordinate national funding and collaborative actions supporting the implementation of the JPIAMR Strategic Research Agenda (SRA). JPIAMR EXEDRA will be the second Coordinated Support Action (CSA) for this Joint Programming Initiative (JPI) and essentially build on the work of the first CSA (JPIAMR), which ended February 2016. It will provide a strong support structure for the JPIAMR during the forthcoming implementation and expansion phaseby maintaining a continuity between the objectives, tasks and Work Packages of EXEDRA and JPIAMR. Support facilitated by the CSA EXEDRA will ensure that the ethos of joint programming in the area antimicrobial drug resistance becoming embedded within JPIAMR member’s research and innovation policies and programmes. EXEDRA will have the following work packages: WP1 Management and coordination; WP2 Strategy, governance, and long term sustainability; WP3 Internationalisation and capacity extension; WP4 Alignment with policy and industry; WP5 Research alignment; WP6 Communication, dissemination, and advocacy. EXEDRA will significantly contribute to the delivery of the JPIAMR SRA combined with the JPI-EC-AMR effort and the experience of the JPIAMR members. EXEDRA (and the JPIAMR) will support transnational cooperation to to pool substantial and long-term research funding and serve to complement other initiatives in the AMR area. It will create momentum with the potential to move the frontiers forward and offer new opportunities for industry, new tools for society, and new evidence-based data for policy makers, which will inspire other necessary initiatives.